The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages

Pediatric Pulmonology

Volumn 49, Issue 3, 2014, Pages

  Zobell, Jeffery T ^a,b   Kemper, Andrea L ^a   Young, David C ^c,d  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b Intermountain Cystic Fibrosis Pediatric Center   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Intermountain Cystic Fibrosis Adult Center   (United States)

Author keywords

antibiotics; beta lactams; Burkholderia cenocepacia; Inquilinus limosus; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTICS; BETA-LACTAMS; BURKHOLDERIA CENOCEPACIA; INQUILINUS LIMOSUS; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA INFECTIONS; CARBAPENEMS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS STUTZERI; RHODOSPIRILLACEAE; THIENAMYCINS; TOBRAMYCIN; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84894286529     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22798     Document Type: Article

References (18)

1. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
2. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA,. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011; 46: 987-990.
3. Prescott WA, Jr., National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16: 262-269.
4. Zobell JT, Young DC, Waters CD, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol 2012; 47: 1147-1158.
5. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol 2013; 48: 107-122.
6. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA,. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 1997; 41: 2053-2056.
7. Mouton JW, den Hollander JG,. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-936.
8. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatr Pulmonol 2013 (in press).
9. Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K,. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther 2011; 33: 1844-1850.
10. Bulitta JB, Landersdorfer CB, Huttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U, Sorgel F,. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2010; 54: 1275-1282.
11. Zobell JT, Young DC, Chatfield BA,. Intermittent and extended-infusion beta-lactam utilization in cystic fibrosis. Pediatr Pulmonol 2012 (in press).
12. Cirillo I, Vaccaro N, Redman R, Black PL, Kearns G,. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis. J Clin Pharmacol 2012; 52: 1645-1653.
13. Vaccaro NCI, Redman R, Black P, Kearns GL,. Pharmacokinetics of doripenem in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 2011; 183: A5728.
14. Agency EM,. Doribax: summary of product characteristics [online].
15. Chen Y, Garber E, Zhao Q, Ge Y, Wikler MA, Kaniga K, Saiman L,. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 2510-2511.
16. Traczewski MM, Brown SD,. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006; 50: 819-821.
17. Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS,. Continuous-infusion antipseudomonal beta-lactam therapy in patients with cystic fibrosis. P & T 2011; 36: 723-763.
18. Doribax® Approved Package labeling, 2009, Ortho McNeil Janssen.